Siponimod for treating secondary progressive multiple sclerosis: Appraisal consultation document

DRAFT guidance does not recommend use, within its marketing authorisation, because clinical evidence is limited, the cost-effectiveness estimates are uncertain, and none of the analyses reflect the committee’s preferred assumptions.

Source:

National Institute for Health and Care Excellence